Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
Teriflunomide
Mylan Pharmaceuticals Limited
L04AA31
teriflunomide
Immunosuppressants
Multiple Sclerosis, Relapsing-Remitting
Teriflunomide Mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 of the SmPC for important information on the population for which efficacy has been established).
Revision: 1
Authorised
2022-11-09
34 PACKAGE LEAFLET 35 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TERIFLUNOMIDE MYLAN 14 MG FILM-COATED TABLETS teriflunomide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Teriflunomide Mylan is and what it is used for 2. What you need to know before you take Teriflunomide Mylan 3. How to take Teriflunomide Mylan 4. Possible side effects 5. How to store Teriflunomide Mylan 6. Contents of the pack and other information 1. WHAT TERIFLUNOMIDE MYLAN IS AND WHAT IT IS USED FOR WHAT TERIFLUNOMIDE MYLAN IS Teriflunomide Mylan contains the active substance teriflunomide which is an immunomodulatory agent and adjusts the immune system to limit its attack on the nervous system. WHAT TERIFLUNOMIDE MYLAN IS USED FOR Teriflunomide is used in adults and in children and adolescents (10 years of age and older) to treat relapsing remitting multiple sclerosis (MS). WHAT MULTIPLE SCLEROSIS IS MS is a long-term illness that affects the central nervous system (CNS). The CNS is made up of the brain and spinal cord. In multiple sclerosis, inflammation destroys the protective sheath (called myelin) around the nerves in the CNS. This loss of myelin is called demyelination. This stops nerves from working properly. People with relapsing form of multiple sclerosis will have repeated attacks (relapses) of physical symptoms caused by their nerves not working properly. These symptoms vary from patient to patient but usually involve: difficulty walking vision problems balance problems. Symptoms may disappear com Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Teriflunomide Mylan 14 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 14 mg of teriflunomide. Excipient(s) with known effect Each tablet contains 85.4 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) Pale blue to pastel blue coloured, round, biconvex, film-coated tablets debossed with ‘T’ on one side and ‘1’ on the other side, approximately 7.6 mm in diameter. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Teriflunomide Mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The treatment should be initiated and supervised by a physician experienced in the management of multiple sclerosis. Posology _Adults _ In adults, the recommended dose of teriflunomide is 14 mg once daily. _Paediatric population (10 years and older) _ In paediatric patients (10 years of age and above), the recommended dose is dependent on body weight: - Paediatric patients with body weight > 40 kg: 14 mg once daily. - Paediatric patients with body weight ≤ 40 kg: 7 mg once daily. Paediatric patients who reach a stable body weight above 40 kg should be switched to 14 mg once daily. Teriflunomide Mylan is only available as 14 mg film-coated tablets. Thus, it is not possible to administer Teriflunomide Mylan to patients that require less than a full 14 mg dose. If an alternate dose is required, other teriflunomide products offering such an option should be used. Special populations 3 _Elderly population _ Teriflunomide should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy. _Renal impairment _ No dose adjustment is Lestu allt skjalið